Wealth Enhancement Advisory Services LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 1.8% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 311,600 shares of the company's stock after buying an additional 5,557 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in AstraZeneca were worth $22,903,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in AZN. Brighton Jones LLC lifted its stake in shares of AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after purchasing an additional 2,789 shares during the period. Rhumbline Advisers raised its position in shares of AstraZeneca by 1.4% in the 4th quarter. Rhumbline Advisers now owns 29,123 shares of the company's stock worth $1,908,000 after buying an additional 404 shares during the period. Principal Financial Group Inc. purchased a new position in shares of AstraZeneca in the 4th quarter worth $31,192,000. D.A. Davidson & CO. raised its position in shares of AstraZeneca by 39.7% in the 4th quarter. D.A. Davidson & CO. now owns 36,116 shares of the company's stock worth $2,366,000 after buying an additional 10,257 shares during the period. Finally, New York State Common Retirement Fund raised its position in shares of AstraZeneca by 7.4% in the 4th quarter. New York State Common Retirement Fund now owns 133,043 shares of the company's stock worth $8,717,000 after buying an additional 9,124 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, BNP Paribas started coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $85.00.
Check Out Our Latest Stock Analysis on AstraZeneca
AstraZeneca Stock Down 1.1%
NASDAQ:AZN opened at $69.95 on Friday. The company has a market capitalization of $216.94 billion, a price-to-earnings ratio of 28.09, a price-to-earnings-growth ratio of 1.28 and a beta of 0.38. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The stock has a 50-day simple moving average of $70.34 and a 200 day simple moving average of $70.42. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the previous year, the firm posted $2.06 earnings per share. AstraZeneca's quarterly revenue was up 7.2% compared to the same quarter last year. Sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
